News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - BLA/NDA/ANDA
Newron Pharma (NWRN) To Re-Submit U.S. NDA For Xadago (Safinamide) 7/26/2016
FDA Spurns Ocular Therapeutix (OCUL)'s Post-Operative Eye Pain Treatment 7/25/2016
Amid Trial Concerns, FDA Delays Approval Decision for Merck & Co. (MRK)'s C. Diff Drug, New PDUFA Date Set 7/22/2016
FDA Rejects Valeant (VRX) Glaucoma Drug, Raises Concerns Over Manufacturing Issues 7/22/2016
Puma Biotech (PBYI) Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer 7/22/2016
Amgen (AMGN) And UCB Submit Biologics License Application For Romosozumab To The FDA 7/22/2016
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Receive Positive CHMP Opinion For Cabometyx (Cabozantinib) For The Treatment Of Advanced RCC In Adults Following Prior VEGF-Targeted Therapy 7/22/2016
FDA Panel Says Valeant (VRX)'s Psoriasis Med Should be Approved with Risk Plan 7/20/2016
Lannett (LCI) Announces Receipt Of FDA Acceptable Filing Letter For Fentanyl Patch ANDA 7/20/2016
FDA Spurns Novartis AG (NVS)'s Copy of Amgen (AMGN) Blockbuster Neulasta 7/19/2016
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce FDA Approval Of BELVIQ XR (Lorcaserin Hcl) Extended-Release Tablets 7/19/2016
FDA Panel Divided on Valeant (VRX)'s Psoriasis Drug Suicide Risk 7/18/2016
Clinuvel To File New Drug With FDA 7/18/2016
Elite Pharma (ELI) Release: FDA Issues Complete Response Letter for SequestOx New Drug Application 7/18/2016
Elite Pharma (ELI) To Host Conference Call To Discuss SequestOx Complete Response Letter On Monday, July 18, 2016 At 8:30 AM EDT 7/18/2016
Synergy Pharma Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program 7/15/2016
Fera Pharmaceuticals And Oakwood Laboratories Announce ANDA Approval Of Levothyroxine Sodium For Injection 7/15/2016
FDA Hits DMD Drugmaker Santhera (SANN.SW) With Lengthy Delay 7/14/2016
Amgen (AMGN) Inches Closer to Selling Cheaper Version of AbbVie (ABBV)'s Blockbuster Humira 7/13/2016
Amgen (AMGN) To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab 7/12/2016
Cipher Pharma (DND.TO) Announces Ozenoxacin Accepted For Review By Health Canada 7/12/2016
FDA Staff Says Novartis AG (NVS) Copy of Amgen (AMGN)'s Blockbuster Enbrel is 'Highly Similar' 7/11/2016
Lannett (LCI) Announces Approval And Launch Of Paroxetine Extended Release Tablets USP, 12.5 Mg, 25 Mg, 37.5 Mg 7/11/2016
Sanders, Other Lawmakers Urge FDA Approval Of Generic Crestor 7/8/2016
FDA Staff Says Amgen (AMGN) Biosimilar is 'Highly Similar' to AbbVie (ABBV)'s Blockbuster Humira 7/8/2016
Teligent Receives Two FDA Approvals For Topical Prescription Portfolio 7/8/2016
TherapeuticsMD (TXMD) Announces New Drug Application Submission For Yuvvexy (TX-004HR) 7/8/2016
Medicure (MCU) Receives Response Letter From FDA On AGGRASTAT sNDA For New Indication 7/8/2016
Cempra (CEMP) Stashes Cash to Focus on Marketing Its New Anti-Bacterial Once FDA Gives It Thumb’s-Up 7/7/2016
IntelliPharmaCeutics Reports Update On Rexista XR: FDA Grants Waiver Of NDA Filing Fee, And Topline Pharmacokinetics Results Indicate No Food Effect 7/5/2016
Takeda (TKPYY) Submits A New Drug Application For Novel, Oral Proteasome Inhibitor Ixazomib In Japan 7/5/2016
DURECT (DRRX)’s PDUFA Date for Remoxy NDA of Sept 25 Unchanged 7/1/2016
GeoVax Labs Inc. (GOVX.OB) Announces Filing Of Investigational New Drug Application For HIV Human Clinical Trial 7/1/2016
Array BioPharma (ARRY) Submits Binimetinib New Drug Application To U.S. FDA 7/1/2016
TherapeuticsMD (TXMD) Announces Filing Timeline For Yuvvexy (TX-004HR) New Drug Application 6/30/2016
Aratana Therapeutics (PETX) Files For FDA Approval Of NOCITA (Bupivacaine Liposome Injectable Suspension) 6/30/2016
Lipocine (LPCN) Shares Slump as FDA Does Not Approve NDA for Testosterone Drug LPCN 1021 6/29/2016
Speedy Review for Genentech (RHHBY)’s OCREVUS, Action Date December 28 6/29/2016
Horizon Pharma (HZNP) Submits Supplemental New Drug Application For RAVICTI (Glycerol Phenylbutyrate) Oral Liquid To Expand Age Range For Management Of Urea Cycle Disorders 6/29/2016
FDA Advisory Committee Meeting on August 4 for Egalet’s ARYMO; PDUFA Date is October 14 6/28/2016
Teva (TEVA) Announces FDA Acceptance Of New Drug Applications For Fluticasone Propionate/Salmeterol And Fluticasone Propionate RespiClick Inhalers 6/28/2016
Lannett (LCI) Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL 6/28/2016
Kitov (KTOV)'s Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead Of Planned NDA Filing With U.S. FDA 6/28/2016
Medimetriks Pharmaceuticals, Inc. Submits A New Drug Application To FDA For Ozenoxacin Cream, 1%, A Novel Impetigo Treatment 6/27/2016
Advanced Accelerator Applications Announces FDA Priority Review for Lutathera; PDUFA Target Action Date is December 28, 2016 6/27/2016
Sarepta (SRPT)'s Study Period Extension May Help Gain DMD Drug Approval in the Long Run 6/24/2016
Allergan (AGN) Announces D&A Pharma Approval Of Supplemental New Drug Application (Snda) For AVYCAZ (Ceftazidime And Avibactam) 6/23/2016
FDA Grants Priority Review For NicOx SA (COX.PA)'s AC-170 New Drug Application 6/21/2016
Mitsubishi Tanabe Submits New Drug Application For Edaravone To Treat ALS In The United States 6/20/2016
Ariad (ARIA) Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan 6/17/2016
Vanda Pharmaceuticals, Inc. (VNDA) Release: FDA Grants Fanapt Three Years Of Marketing Exclusivity for Labeling Changes Relating To Maintenance Treatment Of Schizophrenia 6/16/2016
Allergan (AGN) Announces FDA Acceptance Of The 510(K) Premarket Notification Filing For The XEN Glaucoma Treatment System 6/15/2016
Endo Pharma (ENDP) Announces FDA Advisory Committee Meeting For OPANA ER 6/15/2016
Unclear Whether FDA Took Into Account KemPharm (KMPH)'s Amendment Data in Rejecting Apadaz Application 6/14/2016
Marathon Pharma Announces Submission Of Deflazacort New Drug Application To The FDA 6/14/2016
Charleston Laboratories And Daiichi Sankyo Announce FDA Acceptance Of New Drug Application (NDA) For CL-108 6/13/2016
FDA Advisors Backs Approval for Merck & Co. (MRK)'s Infectious Diarrhea Drug 6/10/2016
Upsher-Smith Laboratories Granted Tentative FDA Approval For Qudexy XR (topiramate) Extended-Release Capsules For Prophylaxis Of Migraine Headache In Adults 6/10/2016
Pfizer (PFE) Announces FDA Advisory Committees’ Recommend ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-Release Capsules For Approval 6/9/2016
Ironwood (IRWD) And Allergan (AGN) Announce Supplemental New Drug Application For 72 Mcg Linaclotide In Chronic Idiopathic Constipation Has Been Accepted For FDA Review 6/9/2016
FDA Questions Merck & Co. (MRK)'s C. Diff Diarrhea Medication’s Efficacy 6/8/2016
Teva (TEVA) Gains Recommendation For Approval From FDA Advisory Committees For VANTRELA ER (Hydrocodone Bitartrate) Extended-Release Tablets CII Formulated With Proprietary Abuse Deterrence Technology 6/8/2016
Sarepta (SRPT) Surges Yet Again, as the FDA Requests More Data About Duchenne’s Drug 6/7/2016
Adamis (ADMP) Stock Tanks After the FDA Rejects Emergency Drug for Severe Allergic Reaction 6/6/2016
Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 6/6/2016
Theravance Biopharma (TBPH) Highlights Acceleration Of Timeline For Filing U.S. New Drug Application For The Closed Triple By GlaxoSmithKline (GSK) And Innoviva 6/3/2016
All Eyes Turn to Sarepta (SRPT) as BioMarin (BMRN) Shutters Its Kyndrisa Duchenne Program 6/2/2016
GlaxoSmithKline (GSK) Eyes Lead in Triple Lung Drug Market with Early 2016 Filing Plan 6/2/2016
FDA Wants Teva (TEVA) to Re-Analyze the Blood Levels of Certain Metabolites of Huntington Disease Drug 5/31/2016
Bad News for AstraZeneca PLC (AZN) is Good News for Relypsa (RLYP) 5/31/2016
Vertex (VRTX) Release: FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI (Lumacaftor/Ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation 5/31/2016
Lexicon Pharma (LXRX) Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome 5/31/2016
Vanda Pharmaceuticals, Inc. (VNDA) Announces FDA Approval Of The Fanapt Supplemental New Drug Application For Maintenance Treatment Of Schizophrenia In Adults 5/27/2016
Sarepta (SRPT) Rockets After the FDA Delays Ruling on DMD Drug 5/26/2016
Flexion (FLXN) Receives Positive Guidance From FDA On New Drug Application (NDA) Submission For Zilretta For Osteoarthritis Of The Knee 5/26/2016
FDA Panel Unanimously Backs Novo Nordisk A/S (NVO)'s Diabetes Combo Drug Ideglira 5/25/2016
Samsung Bioepis’ Biologics License Application For SB2 Infliximab Biosimilar Accepted By U.S. FDA 5/24/2016
Allergan (AGN) Announces FDA Acceptance Of NDA Filing For Oxymetazoline HCI Cream 1.0% 5/24/2016
FDA Staff Questions Usefulness of Sanofi (SNY)’s Diabetes Drug Combo 5/23/2016
Advanced Accelerator Applications Preparing For Lutathera Launch By Scaling Up Production In Ivrea, Italy 5/23/2016
Mylan (MYL) Launches First Generic Doryx Delayed-Release Tablets, 200 mg 5/23/2016
DURECT (DRRX) Announces FDA Advisory Committee Meeting For REMOXY 5/19/2016
Novartis AG (NVS) Ponders Over Using a Medical Device-Like Sales Model for Experimental Cancer Therapy 5/17/2016
Upcoming PDUFA And ANDA Approval Dates Could Catalyze Innovus Pharma And Lipocine Inc. (LPCN) 5/17/2016
Federal Agencies Want to Know More About Clovis Oncology (CLVS)'s Rociletinib Data from Last Fall 5/13/2016
TetraPhase (TTPH) Drops After the FDA Requests More Data for Eravacycline NDA Submission 5/13/2016
Chiasma Chief Says Firm May Challenge FDA Over Rare-Disease Drug Rejection 5/12/2016
Kitov (KTOV) Receives Pre-NDA Meeting Response From FDA For KIT-302, Supporting Its NDA Submission 5/12/2016
Medicure (MCU) Files Application For New AGGRASTAT Product Format 5/11/2016
PharmaEngine, Inc. Announces Korean Ministry Of Food And Drug Safety Accepted The NDA Filing Of ONIVYDE For The Treatment Of Metastatic Pancreatic Cancer 5/11/2016
KemPharm (KMPH) Crashes After the FDA Votes Against Abuse-Deterrent Labeling for Pain Med 5/6/2016
2 Biotechs Investors Should Pick Up Before Key PDUFA Dates 5/5/2016
Kindred Bio (KIN) Submits KIND-010 New Animal Drug Application Technical Section For Chemistry, Manufacturing, And Controls To FDA 5/5/2016
Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval For Lacosamide Tablets (Vimpat) 5/4/2016
FDA Grants Priority Review For Amgen (AMGN)'s Supplemental Biologics License Application For Blincyto (Blinatumomab) 5/4/2016
FDA Grants Priority Review For Eli Lilly (LLY)'s Olaratumab, An Investigational Medicine For Advanced Soft Tissue Sarcoma 5/4/2016
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK) 5/3/2016
Why Sarepta (SRPT) Didn't Start a Big DMD Trial Quicker 5/3/2016
Opko Health (OPK) Release: FDA Accepts Resubmission Of New Drug Application For RAYALDEE 4/28/2016
FDA Spurns Otsuka Pharma, Proteus Digital Health's Drug/Device Combo 4/27/2016
Rounding Up the Experts’ Thoughts on What's Next for Sarepta (SRPT)'s DMD Drug 4/27/2016
FDA Pushes Back PDUFA Date for Dynavax (DVAX)'s Hep B Vaccine HEPLISAV-B 4/27/2016
Cerebain Biotech Today Announced It Plans to Seek FDA Approval 4/27/2016
CFDA Accepts HCV Treatments From Seven Companies For Accelerated Approval 4/27/2016
FDA Panel’s 7-6 Vote Against Sarepta (SRPT)’s DMD Drug Underlines Battle Between Science and Patient Advocates 4/26/2016
Catalyst Pharmaceuticals (CPRX) Must Run Another Study of Its Firdapse Drug: FDA 4/26/2016
Sarepta (SRPT)’s Stock a Rollercoast Ride Prior to Today’s FDA Hearing 4/25/2016
FDA Accepts Lundbeck Inc. (LUN.CO) Resubmission Of New Drug Application For Carnexiv (Carbamazepine) 4/25/2016
Sarepta (SRPT) Craters as the FDA Releases Documents Ahead of Monday’s DMD Drug Hearing 4/22/2016
FDA Craters as the TransEnterix (TRXC) Spurns SurgiBot 510(k) Submission 4/21/2016
FDA Panel Backs Cartiva's Synthetic Cartilage Implant (SCI) 4/21/2016
NicOx SA (COX.PA) Submits New Drug Application For AC-170 To U.S. FDA 4/20/2016
Aralez Announces Several Corporate Updates 4/20/2016
Roche (RHHBY)'s Pharma Head Believes Its First Cancer Immunotherapy Will Win FDA Approval Soon 4/19/2016
Bay Area's Heron (HRTX) Surges as the FDA Finds No Deficiency with SUSTOL NDA, Starts Labeling Discussions 4/19/2016
Synergy Pharma Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation 4/19/2016
Chiasma Crashes on FDA Drug Rejection of Mycapssa 4/18/2016
Clovis Oncology (CLVS) Takes Another Hit After An FDA Panel Votes Against Rociletinib 4/14/2016
FDA Accepts For Priority Review Bristol-Myers Squibb (BMY)’s Supplemental Biologics License Application For Opdivo (Nivolumab) For The Treatment Of Classical Hodgkin Lymphoma Patients 4/14/2016
Shire (SHPG) Submits NDA To FDA For New Formulation Of Vyvanse (Lisdexamfetamine Dimesylate) CII As Chewable Tablets 4/14/2016
Merck & Co. (MRK) Announces FDA Acceptance Of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet 4/13/2016
Clovis Oncology (CLVS)'s Lung Cancer Failure Pain Could be AstraZeneca PLC (AZN)'s Gain 4/13/2016
Vernalis PLC (VNLPY.PK) Announces Successful Completion Of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 4/13/2016
Merck & Co. (MRK) Release: FDA Accepts Supplemental Biologics License Application (sBLA) For KEYTRUDA (Pembrolizumab) In Recurrent Or Metastatic Head And Neck Cancer, And Grants Priority Review 4/13/2016
DURECT (DRRX) Announces FDA Acceptance Of REMOXY NDA, PDUFA Date Of September 25, 2016 4/13/2016
Bio Products Laboratory Announces FDA Submission Of Biologics License Supplement For Gammaplex 10% 4/13/2016
FDA Accepts Genentech (RHHBY)'s BLA and Grants Priority Review for Lung Cancer Drug Atezolizumab 4/12/2016
FDA Panel Unanimously Backs Speedy Approval of Intercept Pharma (ICPT)'s Liver Disease Drug Ocaliva 4/11/2016
FDA Staff Questions Efficacy and Safety Issues of Clovis Oncology (CLVS)'s Lung Cancer Drug 4/8/2016
Vectura (VEC.L) Release: VR315 U.S. ANDA For Generic Advair Diskus Accepted For Filing By FDA And Milestone Payment 4/8/2016
Biofrontera AG Announces NDA Progress Update For BF-200 ALA 4/5/2016
FDA Extends Action Date for Progenics (PGNX), Valeant (VRX)'s NDA for Oral RELISTOR 4/4/2016
ConforMIS Withdraws Application as the FDA Raises Questions on iTotal Hip 4/4/2016
Dynavax (DVAX) Announces FDA Acceptance For Review Of Biologics License Application And PDUFA Action Date For HEPLISAV-B 3/31/2016
Gilead (GILD) Submits New Drug Application To Japan’s Pharmaceutical And Medical Devices Agency For Tenofovir Alafenamide (TAF) For Patients With Chronic Hepatitis B Infection 3/31/2016
Lexicon Pharma (LXRX) Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome 3/31/2016
Acadia (ACAD) Surges as FDA Panel Backs Psychosis Drug Linked to Parkinson’s Disease 3/30/2016
Opko Health (OPK) Falls as the FDA Halts Approval of Rayaldee 3/30/2016
FDA Wants Additional Evaluation of Newron Pharma (NWRN)'s Xadago 3/30/2016
Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 3/30/2016
SoCal's Puma Biotech (PBYI) Delays NDA for Neratinib to Treat Breast Cancer Until Mid-2016 3/29/2016
H. Lundbeck A/S (LUN.CO) Falls After FDA Rejects Brintellix Label Expansion 3/29/2016
FDA Approves Supplemental New Drug Application (sNDA) For Boehringer Ingelheim's STIOLTO RESPIMAT For COPD Health-Related Quality Of Life 3/29/2016
DURECT Corporation (DRRX) Announces Resubmission Of REMOXY New Drug Application To The FDA 3/29/2016
7 Potential Blockbuster Drugs May Hit the Market This Year 3/28/2016
FDA Staff Says Acadia (ACAD)'s Drug for Parkinson's Disease Psychosis Nuplazid is Effective 3/28/2016
Aralez Announces FDA Acceptance Of New Drug Application For YOSPRALA 3/28/2016
Aratana Therapeutics (PETX) Files For Second FDA Approval 3/23/2016
36 DMD Experts Send Letter to the FDA Urging Approval of Sarepta (SRPT)’s Drug 3/22/2016
Raptor (RPTP)’s PROCYSBI New Drug Submission Accepted By Health Canada With Priority Review 3/22/2016
Anacor (ANAC) Announces FDA Acceptance Of NDA For Crisaborole Topical Ointment, 2% For The Treatment Of Mild-To-Moderate Atopic Dermatitis 3/22/2016
Eagle Pharma (EGRX) Plunges as the FDA Rejects Blood Thinner Kangio 3/18/2016
Elite Pharma (ELI) Announces U.S. FDA Priority Review Designation For Sequestox NDA 3/17/2016
Allergan (AGN) Confirms Generic Abraxane Patent Challenge 3/17/2016
Genentech (RHHBY)'s Bladder Cancer Drug Gains Priority Review by the FDA 3/16/2016
Kindred Bio (KIN) Submits Final Major New Animal Drug Application Technical Section For Safety For Zimeta To FDA 3/16/2016
FDA Panel Backs Abbott (ABT)'s Dissolving Stent 3/16/2016
Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Hematological Malignancies 3/15/2016
Aralez Resubmits To FDA New Drug Application For YOSPRALA 3/15/2016
Five Companies Face Big FDA Decisions This Month 3/14/2016
Tesaro (TSRO) Submits New Drug Application For Intravenous Rolapitant To The U.S. FDA 3/14/2016
FDA Wants TSO3 (TOS) to Evaluate Claims Based on the Type and Manufacture of Device 3/14/2016
Sarepta (SRPT) Finally Gets Another Date with the FDA for DMD Drug 3/11/2016
FDA Accepts Amgen (AMGN)'s Supplemental Biologics License Application For The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis 3/11/2016
Three Drugmakers Facing FDA Decisions This Quarter 3/10/2016
Telesta (TSX:TST) Requests Meeting With FDA Over Bladder Cancer Drug, Slashes Jobs by 15% 3/9/2016
Celgene (CELG) Notified Of ANDA Filing For ABRAXANE 3/8/2016
PharmaEngine, Inc. Announces Taiwan FDA Granting The Product License Of ONIVYDE (Irinotecan Liposome Injection) For The Treatment Of Metastatic Pancreatic Cancer 3/7/2016
Vericel (ASTM) Announces FDA Acceptance For Filing Of BLA For MACI For The Treatment Of Symptomatic Cartilage Defects In The Knee 3/7/2016
Merck & Co. (MRK) Release: FDA Accepts Supplemental Biologics License Application (Sbla) For KEYTRUDA (Pembrolizumab) In Advanced Non-Small Cell Lung Cancer 3/7/2016
Heron (HRTX)'s Sustol Finally Gets a Date with the FDA 3/3/2016
Amgen (AMGN) Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) 3/2/2016
FDA Files Genentech (RHHBY)'s Supplemental Biologics License Application Of Xolair (Omalizumab) For Pediatric Allergic Asthma 3/1/2016
FDA Needs More Time, Delays Assigning Action Date for Heron (HRTX)'s SUSTOL NDA 2/29/2016
Allergan (AGN) Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN ANDA 2/29/2016
Egalet Announces FDA Acceptance Of New Drug Application For ARYMO ER (Morphine Sulfate) Extended-Release Tablets 2/29/2016
Baxalta (BXLT) Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings 2/26/2016
PTC Therapeutics (PTCT) Crashes as It Becomes Fourth Company to Be Turned Down this Year by FDA for DMD Drug 2/24/2016
Allergan (AGN) Release: FDA Accepts And Grants Priority Review For AVYCAZ (ceftazidime and avibactam) Supplemental New Drug Application (sNDA) 2/24/2016
FDA Concurs On Clinical Dose For SIGA (SIGA)’s Tecovirimat Antiviral 2/24/2016
Ironwood (IRWD) Announces Filing By Astellas (ALPMY) Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C 2/24/2016
Aratana Therapeutics (PETX) Receives Technical Section Complete Letter For Effectiveness For AT-002 2/23/2016
Astellas (ALPMY) Release: FDA Accepts For Review Supplemental New Drug Application For XTANDI (Enzalutamide) Capsules In Metastatic Castration-Resistant Prostate Cancer With Data From Head-To-Head Studies Of Enzalutamide Versus Bicalutamide 2/23/2016
Three Biotechs Cited as Promising Bets in 2016 With FDA Decisions Pending 2/22/2016
FDA Needs More Time to Review Titan Pharma (TTP)' Probuphine NDA 2/22/2016
Bracco Diagnostics Receives Second U.S. FDA Approval For Barium-Based Products, The First In Computed Tomography 2/22/2016
FDA Accepts Sanofi (SNY) New Drug Application For Once-Daily Fixed-Ratio Combination Of Insulin Glargine And Lixisenatide 2/22/2016
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SNY)s NDA For The Fixed-Ratio Combination (Lixilan) Of Lixisenatide And Insulin Glargine For Type 2 Diabetes Has Been Accepted For Review By The FDA 2/22/2016
Neurelis Finalizes Series A Financing To Advance Lead Program To NDA Filing 2/22/2016
Aratana Therapeutics (PETX) Receives Technical Section Complete Letter For Effectiveness For AT-003 2/22/2016
Spectrum Pharma (SPPI) Announces FDA’s Acceptance Of NDA Filing For Eoquin (Apaziquone For Intravesical Instillation) 2/19/2016
United Therapeutics (UTHR) Receives Paragraph IV Notice Letter For Orenitram 2/19/2016
Catalyst Pharmaceuticals (CPRX) Tanks on FDA Refuse-to-File Letter 2/18/2016
Portola (PTLA) Announces Biologics License Application For Andexanet Alfa Accepted For Review By FDA 2/18/2016
Mylan (MYL)'s ANDA For Generic Advair Diskus Accepted For Filing By FDA 2/18/2016
FDA Spurns Merck & Co. (MRK)'s Cardiovascular Claims for Zetia, Vytorin 2/17/2016
IMPAX Labs (IPXL) Receives FDA Approval For Generic Version Of Adderall XR (Mixed Salts Of A Single-Entity amphetamine product) Capsules, CII 2/17/2016
Cipher Pharma (DND.TO) Announces Sitavig Accepted For Review By Health Canada 2/16/2016
Allergan (AGN) Release: FDA Accepts Supplemental New Drug Application (sNDA) For TEFLARO (ceftaroline fosamil) 2/16/2016
Clovis Oncology (CLVS) Announces Rociletinib New Drug Application Scheduled For Presentation At Upcoming FDA Oncologic Drugs Advisory Committee Meeting 2/12/2016



//-->